Ascendis Fixed Asset Turnover from 2010 to 2025

ASND Stock  USD 167.99  2.00  1.20%   
Ascendis Pharma's Fixed Asset Turnover is decreasing over the years with slightly volatile fluctuation. Overall, Fixed Asset Turnover is expected to go to 3.92 this year. During the period from 2010 to 2025 Ascendis Pharma Fixed Asset Turnover annual values regression line had geometric mean of  1.90 and mean square error of  11.25. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
3.68378346
Current Value
3.92
Quarterly Volatility
4.98981119
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.6 M, Interest Expense of 68.8 M or Selling General Administrative of 298.8 M, as well as many indicators such as Price To Sales Ratio of 19.92, Dividend Yield of 0.0 or Days Sales Outstanding of 187. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
  
Check out the analysis of Ascendis Pharma Correlation against competitors.

Latest Ascendis Pharma's Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Ascendis Pharma AS over the last few years. It is Ascendis Pharma's Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ascendis Pharma's overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Slightly volatile
   Fixed Asset Turnover   
       Timeline  

Ascendis Fixed Asset Turnover Regression Statistics

Arithmetic Mean4.79
Geometric Mean1.90
Coefficient Of Variation104.21
Mean Deviation4.17
Median3.45
Standard Deviation4.99
Sample Variance24.90
Range13.1107
R-Value(0.76)
Mean Square Error11.25
R-Squared0.58
Significance0.0006
Slope(0.80)
Total Sum of Squares373.47

Ascendis Fixed Asset Turnover History

2025 3.92
2024 3.68
2023 2.41
2022 0.4
2021 0.0617
2020 0.0643
2019 0.3

About Ascendis Pharma Financial Statements

Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 3.68  3.92 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
Check out the analysis of Ascendis Pharma Correlation against competitors.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.11)
Revenue Per Share
6.281
Quarterly Revenue Growth
0.263
Return On Assets
(0.17)
Return On Equity
(8.18)
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.